Welcome to our dedicated page for ARTIVA BIOTHERAPEUTICS SEC filings (Ticker: ARTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) SEC filings page provides access to the company’s official U.S. Securities and Exchange Commission disclosures, with AI-powered tools to help interpret complex documents. As a clinical-stage biotechnology company focused on NK cell therapies for autoimmune diseases and cancers, Artiva uses filings such as Forms 8-K, 10-Q and 10-K to report material events, financial results and risk factors.
Recent Form 8-K filings highlighted in the available data include current reports on quarterly financial results, initial safety and translational data for AlloNK (AB-101) in autoimmune disease, and corporate matters such as amendments to the 2024 Equity Incentive Plan and equity award exchanges for certain executives. Other 8-Ks reference FDA Fast Track Designation for AlloNK in refractory rheumatoid arthritis and summarize clinical findings from ongoing Phase 1 and 2 trials combining AlloNK with anti-CD20 monoclonal antibodies after cyclophosphamide and fludarabine conditioning.
Through this page, users can review Artiva’s periodic reports, including 10-Q and 10-K filings, to understand research and development expenses, cash, cash equivalents and investments, net losses, and other financial information the company reports. AI-generated summaries can highlight key sections related to AlloNK’s clinical development, the CAR-NK oncology pipeline, the strategic partnership with GC Cell for NK cell manufacturing technology, and the company’s stated risk factors.
Investors can also reference proxy materials and equity plan amendments to see how Artiva structures compensation and equity incentives, as illustrated by the amendment to the 2024 Equity Incentive Plan approved at the 2025 Annual Meeting. Form 4 insider transaction reports, when available, can be used to monitor equity activity by directors and officers. Real-time updates from EDGAR combined with AI explanations help make ARTV’s regulatory record more accessible to readers who want to understand the company’s clinical, financial and governance disclosures in detail.
Fred Aslan, President, CEO and Director of Artiva Biotherapeutics (ARTV), reported three non-derivative stock transactions. On 05/15/2025 he had 4,472 shares withheld by the issuer to satisfy income tax obligations tied to RSU vesting at a price of $2.13, leaving 412,193 shares beneficially owned. On 08/15/2025 he sold 25,500 shares under a Rule 10b5-1 plan adopted July 23, 2024, at a weighted average sale price of $2.7286 (range $2.60–$2.80), reducing ownership to 386,693 shares. Also on 08/15/2025 another 4,472 shares were withheld for taxes at $2.75, resulting in 382,221 shares owned. The Form 4 was signed by an attorney-in-fact on 08/18/2025.
Raymon Heather, SVP, Research and Development of Artiva Biotherapeutics, Inc. (ARTV), reported two dispositions of common stock tied to restricted stock unit vesting tax-withholdings. On 05/15/2025 the issuer withheld 745 shares at an effective price of $2.13, leaving 42,605 shares beneficially owned. On 08/15/2025 an additional 1,639 shares were withheld at $2.75, leaving 40,966 shares.
The Form 4 was executed by an attorney-in-fact and discloses these routine withholding transactions to satisfy income tax obligations associated with RSU vesting. No derivatives, option exercises, or other types of transactions are reported, and the filing indicates direct ownership by the reporting person.
Neha Krishnamohan, Chief Financial Officer and Director of Artiva Biotherapeutics (ARTV), reported two withholding transactions tied to restricted stock unit vesting. On 05/15/2025 the issuer withheld 1,341 shares at a price of $2.13, leaving 108,659 shares beneficially owned. On 08/15/2025 the issuer withheld 5,813 shares at $2.75, leaving 102,846 shares beneficially owned.
The filing clarifies these were tax-withholding actions to satisfy income tax obligations associated with RSU vesting. The Form 4 was signed by Ms. Krishnamohan on 08/18/2025.
Jennifer Bush, an officer of Artiva Biotherapeutics, reported two non-derivative transactions tied to restricted stock unit vesting. On 05/15/2025 the issuer withheld 1,937 shares at a per-share value of $2.13, leaving 157,512 shares beneficially owned. On 08/15/2025 the issuer withheld 6,409 shares at $2.75, leaving 151,103 shares owned. The filing states these withholdings were made to satisfy income tax obligations associated with the vesting of restricted stock units. The form is signed by Neha Krishnamohan, Attorney-in-Fact on 08/18/2025.
Artiva Biotherapeutics insider Christopher Horan reported two dispositions of common stock tied to restricted stock unit vesting and tax withholding. On 05/15/2025 he had 1,341 shares withheld at an effective price of $2.13, reducing his direct ownership to 83,659 shares. On 08/15/2025 he had 3,577 shares withheld at $2.75, reducing his direct ownership to 80,082 shares. The filing identifies Horan as Chief Tech Operations Officer and was signed by an attorney-in-fact on 08/18/2025. The form states these share reductions "represent shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards," indicating these were not open-market sales but withholding transactions connected to equity compensation.
Artiva Biotherapeutics reported a Form 144 notice showing a planned sale of 25,500 common shares held as Restricted Stock Units that were acquired and are to be sold on 08/15/2025. The broker listed is Morgan Stanley Smith Barney LLC and the planned transaction lists an aggregate market value of $68,850 based on 25,500 shares. The filing records 24,425,762 shares outstanding and identifies NASDAQ as the exchange. The filer reports no securities sold in the prior three months and includes the standard representation that the selling person does not possess undisclosed material adverse information.
The notice appears routine: shares arose from company RSUs, the sale is executed through a major broker, and there are no prior sales reported in the three-month lookback period.